Raphael (Raphy) Mayer, Ph.D.
Founder & CEO
Dr. Mayer conceived Smart Assays in 2005 and successfully led its development to a profitable company, which is recognized today as an established and reliable CRO serving a wide range of life science companies from incubator initiatives to publically traded companies.
Before Smart Assays Dr. Mayer was the head of Assay Development Department in Quark Biotechnology Inc ("QBI"), Ness-Ziona. Israel. Prior to QBI Dr. Mayer was a team leader in InSight Ltd., Rehovot, Israel. Dr. Mayer's academic experience includes postdoctoral fellowship at Rockefeller University, New York, NY, where he worked on phytochrome signal transduction using molecular, transgenic and genetic models in Arabidopsis.
Dr. Mayer earned his Ph.D. at the department of Biological Chemistry of The Hebrew University of Jerusalem, where he discovered c-di-GMP and its role in regulation of bacterial biofilm. Dr. Mayer received his M.Sc., in Biochemistry, with distinction, from The Hebrew University of Jerusalem where he studied the regulation of cellulose synthesis by c-di-GMP specific phosphodiesterases. Dr. Mayer is an author and co-author of 20 scientific publications, several of them in highly prestigious journals including Nature and PNAS.
Director of Operation and Project Manager
Merav Marom Shamur, Ph.D.
Dr. Shamur joined Smart Assays in 2012 as a project manager. Since 2018, Dr. Shamur serves also as a Director of operation. Dr. Shamur is highly qualified biochemist and electrophysiologist
with 15 years of academic and industrial professional experience.
Dr. Shamur earned her Ph.D. at the department of Biological Chemistry of the Hebrew University of Jerusalem, where she discovered different mechanisms of catecholamine release in chromaffin cells. Dr. Shamur received her M.Sc., in Biochemistry, from The Hebrew University of Jerusalem where she developed a fluorescence based analysis of the vesicles translocation to the plasma membrane. Prior to joining Smart Assays, Dr. Shamur was a post-doctoral fellow at the department of Molecular cell biology, Weizmann institute. Dr. Shamur is the author and co-author of six scientific publications.
Veatriki Fraggi Rankis, M.Sc.
Head of QA and Project Manager
Ronny Peri-Naor, Ph.D
Head of Bio-Analytical Unit and Project Manager
Mrs F. Rankis Joined Smart Assays in 2011 as a project manager and head of QA. Mrs. Rankis is highly qualified molecular biologist with 18 years of academic and industrial professional experience. She is a graduate of Tel Aviv University.
Dr. R. Peri-Naor joined Smart Assays in 2016 as a project manager and during 2018 established and became the head of the bio-analytical unit.
Dr Peri-Naor is highly qualified biochemist and bio-analytical researcher with 12 years of academic and industrial professional experience.
Mrs. Rankis received her M.Sc., in Biochemistry, from The Hebrew University of Jerusalem where she studied the expression pattern of osteocalcin in neural crest cells in chick embryos.
Before joining Smart Assays she was a researcher at Quark Pharmaceuticals, Inc. for 9 years. During her career she has gained experience in broad range of molecular biology and histology techniques.
As head of QA in Smart Assays, she precipitated in an official ISO 9001 course of the Standards Institution of Israel (SII) and she has implemented the ISO9001:2015 in the company.
Dr. Peri-Naor earned her Ph.D. at the department of Organic Chemistry of the Weizmann institute of Science. During her Ph.D. in the field of bio-organic chemistry, she synthesized oligonucleotides based nano-structures and studied their interactions with proteins and the ability to utilize them for bio-assays development. Dr. Peri-Naor received her B.Sc. and M.Sc., in Biotechnology engineering from Ben-Gurion University. During her master research in the field of molecular nutrition, she discovered the molecular mechanism by which unsaturated fatty-acids control the expression of the pancreatic lipase. Dr. Peri-Naor is the author and co-author of six scientific publications.
Alexander (Sasha) Faerman, Ph.D.
Dr. Faerman is a highly qualified cell biologist and histologist with 30 years of academic and industrial professional experience in studying of gene expression at the cellular and tissue levels. Scientific areas of his expertise range from developmental biology to molecular human pathology
and preclinical disease models.
Since 2011 Dr. Faerman is with Smart Assays as head of Histopathology unit, and as of July 2019, he began working for 'Merck Israel', and now serves as Histopathology consultant at Smart Assays.
Dr. Faerman served for 4 years as the Senior Director of In Situ Hybridization Unit in Rosetta Genomics. Before that he served as the Head of Histopathology and Hybridoma Unit at QBI.
His academic experience includes working as the investigator (B - equivalent to Associate Professor) in the Institute of Animal Science, Volcani Center (1990-1997).
Dr. Faerman earned his PhD in cell biology from the USSR Academy of Medical Sciences for the discovery and studies of the specific surface antigen of vascular smooth muscle cells. He received his MSc degree (with distinction) in cytology and histology from the Moscow State University. Dr. Faerman is the author and co-author of more than 40 scientific publications and patents.